Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.49 |
| ▸ | BCL6 | P41182 | 1/20 | 0.45 |
| ▸ | DCPS | Q96C86 | 2/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30628471 | 0.80 | ALDH1A1 (0.50) | ADORA2ADCPSNUDT1ALDH1A1HPGD | |
| SCHEMBL27740452 | 0.77 | CYP1A2 (0.47) | ADORA2ADCPSNUDT1ALDH1A1HPGD | |
| SCHEMBL29516287 | 0.77 | BCL6 (0.41) | ADORA2ABCL6DCPSADORA1 | |
| SCHEMBL19662807 | 0.77 | ADORA2A (0.49) | ADORA2ADCPSNUDT1ALDH1A1HPGD | |
| SCHEMBL16755315 | 0.77 | BACE1 (0.56) | ADORA2ADCPSNUDT1ALDH1A1HPGD | |
| SCHEMBL19662784 | 0.77 | CLK1 (0.43) | ADORA2ADCPSNUDT1ALDH1A1HPGD | |
| SCHEMBL29224063 | 0.77 | BCL6 (0.41) | ADORA2ABCL6DCPSADORA1 | |
| SCHEMBL559893 | 0.77 | MAPT (0.47) | ADORA2ABCL6DCPSNUDT1ALDH1A1 | |
| SCHEMBL23002965 | 0.77 | MAPT (0.41) | ADORA2AALDH1A1KDM4EMAOAKCNH2 | |
| SCHEMBL1810679 | 0.77 | PDGFRB (0.37) | ADORA2ACYP1A2KDM4EKCNH2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11447493-B2 | Inhibitors of cyclin-dependent kinases | KINNATE BIOPHARMA INC. | 2022-09-20 | — | — | US | disclosed |
| EP-3787629-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Kinnate Biopharma Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20210053969-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2021-02-25 | — | — | US | disclosed |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-14 | — | — | US | disclosed |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-02 | — | — | US | disclosed |
| US-20140221377-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL MYERS SQUIBB CO (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130131064-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-23 | — | — | US | disclosed |
| US-8309577-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2493892-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120035178-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-09 | — | — | US | disclosed |
| US-20120035189-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-09 | — | — | US | disclosed |
| WO-2011053292-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-05 | — | — | WO | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| EP-0981519-A1 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS | Sugen, Inc. (US) | 2000-03-01 | — | — | EP | disclosed |
| WO-1998050370-A1 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS | SUGEN, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | ADORA2A 218/4885BCL6 4122/4885DCPS 1350/4885 |
| US-20120035189-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | ADORA2A 218/4885BCL6 4122/4885DCPS 1350/4885 |
| US-20120035178-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | ADORA2A 218/4885BCL6 4122/4885DCPS 1350/4885 |
| US-20210053969-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK2, CCNK, CDK1 | ADORA2A 3905/4885BCL6 442/4885DCPS 1363/4885 |
| US-11447493-B2 | Inhibitors of cyclin-dependent kinases | CDK2, CCNK, CDK1 | ADORA2A 3905/4885BCL6 442/4885DCPS 1363/4885 |
| US-20140221377-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | ADORA2A 218/4885BCL6 4122/4885DCPS 1350/4885 |
| US-20130131064-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | ADORA2A 218/4885BCL6 4122/4885DCPS 1350/4885 |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | ADORA2A 218/4885BCL6 4122/4885DCPS 1350/4885 |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | ADORA2A 218/4885BCL6 4122/4885DCPS 1350/4885 |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | ADORA2A 218/4885BCL6 4122/4885DCPS 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.